JP2024527001A5 - - Google Patents
Info
- Publication number
- JP2024527001A5 JP2024527001A5 JP2024504491A JP2024504491A JP2024527001A5 JP 2024527001 A5 JP2024527001 A5 JP 2024527001A5 JP 2024504491 A JP2024504491 A JP 2024504491A JP 2024504491 A JP2024504491 A JP 2024504491A JP 2024527001 A5 JP2024527001 A5 JP 2024527001A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- pharmaceutical composition
- dose
- aniflorumab
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163225974P | 2021-07-27 | 2021-07-27 | |
| US63/225,974 | 2021-07-27 | ||
| US202163254663P | 2021-10-12 | 2021-10-12 | |
| US63/254,663 | 2021-10-12 | ||
| PCT/EP2022/070860 WO2023006700A1 (en) | 2021-07-27 | 2022-07-26 | Treatment of lupus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024527001A JP2024527001A (ja) | 2024-07-19 |
| JP2024527001A5 true JP2024527001A5 (https=) | 2025-08-05 |
Family
ID=83059135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024504491A Pending JP2024527001A (ja) | 2021-07-27 | 2022-07-26 | ループスの治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250326850A1 (https=) |
| EP (1) | EP4377349A1 (https=) |
| JP (1) | JP2024527001A (https=) |
| KR (1) | KR20240038773A (https=) |
| AU (1) | AU2022317215A1 (https=) |
| CA (1) | CA3226744A1 (https=) |
| IL (1) | IL310241A (https=) |
| TW (1) | TW202340245A (https=) |
| WO (1) | WO2023006700A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USD1120170S1 (en) * | 2024-03-28 | 2026-03-24 | Karsten Manufacturing Corporation | Golf club head |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0939121B2 (de) | 1989-09-12 | 2007-12-26 | AHP Manufacturing B.V. | TFN-bindende Proteine |
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| DK0752248T3 (da) | 1992-11-13 | 2000-11-13 | Idec Pharma Corp | Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig |
| DE69534530T2 (de) | 1994-08-12 | 2006-07-06 | Immunomedics, Inc. | Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper |
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| PT2281843T (pt) | 2000-06-16 | 2017-01-02 | Human Genome Sciences Inc | Anticorpos que se ligam imunoespecificamente a blys |
| KR101225299B1 (ko) | 2003-12-10 | 2013-01-24 | 메다렉스, 인코포레이티드 | 인터페론 알파 항체 및 그의 용도 |
| US7662381B2 (en) | 2004-06-21 | 2010-02-16 | Medarex, Inc. | Interferon alpha receptor 1 antibodies and their uses |
| KR20160070165A (ko) | 2008-02-08 | 2016-06-17 | 메디뮨 엘엘씨 | Ｆｃ 리간드 친화성이 감소된 항-ＩＦＮＡＲ１ 항체 |
| CA2772921A1 (en) | 2009-09-03 | 2011-03-10 | Medimmune, Llc | Type 1 interferon diagnostic |
| TWI694836B (zh) | 2014-05-16 | 2020-06-01 | 英商葛蘭素史克智慧財產管理有限公司 | 抗體調配物 |
| RS64263B1 (sr) | 2015-08-19 | 2023-07-31 | Astrazeneca Ab | Stabilna anti-ifnar1 formulacija |
| CN106243226B (zh) | 2016-08-05 | 2019-02-12 | 北京智仁美博生物科技有限公司 | 抗人ifnar1的抗体及其用途 |
-
2022
- 2022-07-26 KR KR1020247006291A patent/KR20240038773A/ko active Pending
- 2022-07-26 AU AU2022317215A patent/AU2022317215A1/en active Pending
- 2022-07-26 EP EP22758427.3A patent/EP4377349A1/en active Pending
- 2022-07-26 JP JP2024504491A patent/JP2024527001A/ja active Pending
- 2022-07-26 WO PCT/EP2022/070860 patent/WO2023006700A1/en not_active Ceased
- 2022-07-26 US US18/291,671 patent/US20250326850A1/en active Pending
- 2022-07-26 TW TW111127870A patent/TW202340245A/zh unknown
- 2022-07-26 CA CA3226744A patent/CA3226744A1/en active Pending
- 2022-07-26 IL IL310241A patent/IL310241A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4114465B1 (en) | Anti-ifnar1 dosing regime for subcutaneous injection | |
| AU2021356122B2 (en) | Treatment of flares in lupus | |
| TW202400234A (zh) | 使用ｆｃｒｎ拮抗劑治療大疱性類天皰瘡之方法 | |
| JP2024518735A5 (https=) | ||
| US20250002589A1 (en) | Treatment of cutaneous lupus erythematous | |
| TW202308691A (zh) | 狼瘡性腎炎之治療 | |
| JP2024527001A5 (https=) | ||
| JP2024519196A5 (https=) | ||
| JP2024516886A5 (https=) | ||
| US20250002591A1 (en) | Inhibitor of type 1 interferon receptor steroid sparing in systemic lupus erythermatosus patients | |
| KR20240038773A (ko) | 루푸스의 치료 | |
| CN121127499A (zh) | 狼疮的治疗 | |
| CN117337305A (zh) | 系统性红斑狼疮患者中的1型干扰素受体抑制剂类固醇节制 | |
| JP2025533978A (ja) | ループスの治療 | |
| EA052183B1 (ru) | Лечение кожной красной волчанки | |
| CN117677638A (zh) | 狼疮的治疗 | |
| JP2023548848A (ja) | ループスを処置するための方法および組成物 | |
| HK40087032B (en) | Anti-ifnar1 dosing regime for subcutaneous injection | |
| HK40087032A (en) | Anti-ifnar1 dosing regime for subcutaneous injection | |
| CN117157099A (zh) | 用于皮下注射的抗ifnar1给药方案 |